Solstice Oncology

Solstice Oncology is a clinical-stage biotechnology company founded by several large venture capital institutions. The company focuses on the development of HBM4003 and is committed to accelerating the global development and commercialization of HBM4003 outside of Greater China. HBM4003 (Proluskab, Prulsumab), is the world's first fully human heavy-chain only anti-CTLA-4 antibody (HCAb) to enter the clinical stage, developed by Harbour BioMed through its proprietary Harbour Mice® platform.